IDiyas

For the Inventor, By the Inventor

Gyeonggi-do, South Korea

An Sung Kwon

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 5.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Gwangju, KR (2015)
  • Gwangju-si, KR (2017)
  • Gyeonggi-do, KR (2019 - 2024)

Company Filing History:

goldMedal12 out of 68 
 
Intron Biotechnology, Inc.
 patents
silverMedal1 out of 1 
 
Intron Blotechnology, Inc.
 patent

Years Active: 2015-2024

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 11970700 - Genetic element E3 for enhanced intracellular expression of target protein encoded in RNA therapeutics (2024-04-30),
2. 11844818 - bacteriophage Aer-HYP-3 and use thereof for inhibiting growth ofbacteria (2023-12-19),
3. 11679138 - Vibrio parahaemolyticus bacteriophage Vib-PAP-7 and use of same for inhibiting vibrio parahaemolyticus bacteria proliferation (2023-06-20),
4. 11679137 - bacteriophage Vib-PAP-4 and use thereof in inhibiting proliferation ofbacteria (2023-06-20),
5. 11439677 - [object Object] (2022-09-13),
6. 11351210 - bacteriophage Lac-GAP-3 and use thereof in inhibiting proliferation ofbacteria (2022-06-07),
7. 11020442 - Vibrio parahaemolyticus bacteriophage Vib-PAP-2 and use thereof for inhibiting proliferation of (2021-06-01),
8. 10898531 - bacteriophage Vib-PAP-5 and use thereof for suppressing proliferation ofbacteria (2021-01-26),
9. 10751377 - Vibrio parahaemolyticus bacteriophage Vib-PAP-1 and use thereof for inhibiting proliferation of vibrio parahaemolyticus (2020-08-25),
10. 10722544 - bacteriophage Str-INP-1 and use of the same for inhibiting the proliferation of (2020-07-28),
11. 10226060 - Lactococcus garvieae bacteriophage Lac-GAP-1 and use thereof in suppressing proliferation of lactococcus garvieae bacteria (2019-03-12),
12. 9539294 - [object Object] (2017-01-10),
13. 8961935 - MRI contrast agent coated with carboxylated mannan and method for producing the same (2015-02-24),

Title: An Sung Kwon: Innovator in RNA Therapeutics and Bacteriophage Research

Introduction: An Sung Kwon, an esteemed inventor based in Gyeonggi-do, South Korea, has made significant contributions to the fields of RNA therapeutics and bacteriophage research. With 13 patents to his name, Kwon’s work focuses on enhancing the efficacy of RNA molecules and developing solutions to combat bacterial infections.

Latest Patents: Among Kwon's latest innovations are two notable patents. The first is related to a genetic element “E3,” which enhances the intracellular expression of target proteins encoded in RNA therapeutics, including mRNA vaccines and RNA medicines. This invention outlines an RNA molecule integrating the genetic element “E3,” a plasmid for synthesizing said RNA, and methods for utilizing this synthesized RNA as therapeutics.

The second patent involves the Myoviridae bacteriophage Aer-HYP-3, which was isolated from nature and shown to be capable of inhibiting bacterial growth. This invention presents a method for preventing and treating bacterial diseases with a composition that includes this unique bacteriophage as an active ingredient.

Career Highlights: An Sung Kwon’s career reflects his dedication to advancing biological and medical technologies. He has worked at organizations such as Intron Biotechnology, Inc., where he applied his expertise in genetic research to drive innovation and contribute to solutions that address critical health issues.

Collaborations: Throughout his career, Kwon has collaborated with talented individuals, including Seong Jun Yoon and Sang Hyeon Kang. These partnerships have facilitated the sharing of ideas and driven successful research outcomes in their respective fields.

Conclusion: An Sung Kwon stands out as a pioneering inventor in the realm of RNA therapeutics and bacteriophage research. His 13 patents underscore his commitment to innovation and his impactful contributions to improving health solutions against bacterial infections and advancing RNA technology. The advancements stemming from Kwon's research are likely to have lasting benefits in the medical field, shaping future therapies and treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…